Angle says Parsortix system could replace cancer tissue biopsy
Angle says Parsortix system could replace cancer tissue biopsy
Read moreMon, 17th Feb 2020 15:25
Angle says Parsortix system could replace cancer tissue biopsy
Read moreAngle cancer study delayed as accreditation process for labs starts
Read moreTRADING UPDATES: Harvest Minerals sales jump; Quartix earnings to rise
Read moreEXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair
Read moreAngle first-half loss widens, crucial FDA decision expected this year
Read moreIN BRIEF: Angle notes studies supporting Parsortix system in cancer
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIN BRIEF: Angle's Parsortix used in Spanish study to find cancer
Read moreIN BRIEF: Angle's Parsortix enables gene analysis in cancer study
Read moreTRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million
Read moreTRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident
Read more(Sharecast News) - Liquid biopsy company Angle has agreed a pharma services contract with another new customer, it announced on Wednesday, for its recently-established pharma services business.
Read moreIN BRIEF: Angle's Parsortix successfully used to harvest cancer cells
Read moreIN BRIEF: Angle raises GBP20.0 million to fund FDA approval drive
Read moreIN BRIEF: Angle to raise GBP20 million through shares placing
Read more